FARXIGA Market Size, Forecast, and Emerging Insight - 2032

“FARXIGA Market Size, Forecast, and Emerging Insight - 2032” report provides comprehensive insights about FARXIGA for myocardial infarction in the seven major markets. A detailed picture of the FARXIGA for myocardial infarction in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the FARXIGA for myocardial infarction. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the FARXIGA market forecast analysis for myocardial infarction in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in myocardial infarction.

Drug Summary

FARXIGA (known as FORXIGA outside the US) (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor. Research has shown FARXIGA’s efficacy in preventing and delaying cardiorenal disease while protecting the organs - important findings given the underlying links between the heart, kidneys, and pancreas.

FARXIGA is approved in adults and children aged 10 and above for treating insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. FARXIGA is also approved for HFrEF and CKD treatment based on the findings of the DAPA-HF and DAPA-CKD Phase III trials.

FARXIGA is currently being tested in the DAPA-MI Phase III trial, a first-of-its-kind, registry-based randomized controlled trial in patients without type 2 diabetes following an acute MI or heart attack. The DAPA-MI trial is conducted in collaboration with Uppsala Clinical Research Center (UCR) and Myocardial Ischaemia National Audit Project (MINAP) in the UK.

As per the company’s Q3 2022 report, data readouts from the Phase III (DAPA-MI) trial are anticipated by 2H 2023. With an estimated key regulatory submission acceptance after 2023.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the FARXIGA description, mechanism of action, dosage and administration, research and development activities in myocardial infarction.
• Elaborated details on FARXIGA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the FARXIGA research and development activities in myocardial infarction across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around FARXIGA.
• The report contains forecasted sales of FARXIGA for myocardial infarction till 2032.
• Comprehensive coverage of the late-stage emerging therapies for myocardial infarction.
• The report also features the SWOT analysis with analyst views for FARXIGA in myocardial infarction.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

FARXIGA Analytical Perspective

In-depth FARXIGA Market Assessment

This report provides a detailed market assessment of FARXIGA for myocardial infarction in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

FARXIGA Clinical Assessment

The report provides the clinical trials information of FARXIGA for myocardial infarction covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for myocardial infarction is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence FARXIGA dominance.
• Other emerging products for myocardial infarction are expected to give tough market competition to FARXIGA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of FARXIGA in myocardial infarction.
• Our in-depth analysis of the forecasted sales data of FARXIGA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the FARXIGA in myocardial infarction.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of FARXIGA?
• What is the clinical trial status of the study related to FARXIGA in myocardial infarction and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the FARXIGA development?
• What are the key designations that have been granted to FARXIGA for myocardial infarction?
• What is the forecasted market scenario of FARXIGA for myocardial infarction?
• What are the forecasted sales of FARXIGA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to FARXIGA for myocardial infarction?
• Which are the late-stage emerging therapies under development for the treatment of myocardial infarction?

This product will be delivered within 2 business days.